147) a consequence of its functional roles in cancer cell and absence in normal tissue, |
148) ng sophistication in our understanding of cancer cell biology, molecular imaging off |
149) that fibroblasts confer effects on breast cancer cell growth and survival. |
150) endogenous pseudogene in the promotion of cancer cell growth in vitro and tumor grow |
151) n that loss of SALL4 inhibits endometrial cancer cell growth in vitro and tumorigeni |
152) verexpression of ANKRD18B suppressed lung cancer cell growth. |
153) genetic modifications and inhibit bladder cancer cell growth. |
154) the HNF-1β-overexpressing human ovarian cancer cell line RMG2 using short hairpin |
155) ms of bufalin in the human hepatocellular cancer cell line SK-Hep1. |
156) pression of HNF-1β in the serous ovarian cancer cell line, Hey, resulted in slowed |
157) oreover, RANKL expression was measured in cancer cell lines (BICR3, BICR56) by immun |
158) heir in vitro antitumor activity in human cancer cell lines (HTLA-230 neuroblastoma, |
159) F1B showed a positive correlation in both cancer cell lines and GC specimens. |
160) -424044 were evaluated against ten canine cancer cell lines for antiproliferative ef |
161) inhibited the cell growth of four bladder cancer cell lines in a dose- and time-depe |
162) owed potential cytotoxicity against human cancer cell lines with IC50 ranging from 1 |
163) ferative activity against multiple canine cancer cell lines, although GS-343074 was |
164) ancer-related processes, namely in breast cancer cell lines, and underline the relev |
165) Here, using patient tumors and cancer cell lines, we identify the NF-κB |
166) ncreased ANKRD18B mRNA expression in lung cancer cell lines. |
167) Moreover, SV37 inhibits growth of breast cancer cell lines. |
168) e and reduced BRCA-1 expression in breast cancer cell lines. |
169) and tumor samples and epithelial ovarian cancer cell lines. |
170) s to SB and FC in ovarian and endometrial cancer cell lines. |
171) degraded this ECM-derived HGF stimulated cancer cell migration (1.5- to 24-fold). |
172) n cancers and has recently been linked to cancer cell motility as a context-dependen |
173) weight gain increases ER-positive breast cancer cell proliferation and reduces tumo |
174) TGF-β has paradoxical effects on cancer cell proliferation, as it suppresse |
175) neered microenvironment influenced breast cancer cell proliferation, differentiation |
176) eutic strategies aiming to overcome colon cancer cell resistance to Dox. |
177) a PPARγ inactive TZD that affects breast cancer cell viability. |
178) on of caspases-3, -7 and -9 in the breast cancer-derived cell lines MCF7 and MDA-MB- |
179) Cancer patients with comorbid conditions h |
|